Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology And US Dominate Daiichi's New Mid-Term Plan

Vision Beyond Core ADCs

Executive Summary

Major Japanese firm sets targets under a new mid-term plan that envisages the US oncology sector leading growth and revenues, and also casts an eye to novel assets beyond three pillar antibody-drug conjugates and new digital technologies.

You may also be interested in...



EU Accelerated Approval Nod For Daiichi Sankyo/AZ’s Enhertu

Daiichi-Sankyo has received a CHMP positive opinion for use of the antibody-drug conjugate in HER2-positive breast cancer, making this the third major market for the product.

Sanofi Goes Big On Asia Vaccines With Singapore Investment

French giant makes its biggest single investment to date in Asia as it prepares to build up regional vaccine production capacity, in part to help prepare for future pandemics. 

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144115

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel